The endocannabinoid system and cardiometabolic risk

Atherosclerosis

Volumn 199, Issue 2, 2008, Pages 248-256

  Szmitko, Paul E ^b   Verma, Subodh ^a  

^a St Michael's Hospital (SV)   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Atherosclerosis; Cannabinoid receptors; Cardiometabolic syndrome; Endocannabinoids

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; RIMONABANT; SULFONYLUREA; TETRAHYDROCANNABINOL; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ANXIETY; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG WITHDRAWAL; ENERGY BALANCE; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; HUMAN; INSOMNIA; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPOPROTEIN BLOOD LEVEL; METABOLIC DISORDER; METABOLIC SYNDROME X; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHOBIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUICIDE ATTEMPT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ABDOMINAL FAT; ANIMALS; APPETITE; ATHEROSCLEROSIS; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; ENDOCANNABINOIDS; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS, HDL; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; OBESITY; RECEPTORS, CANNABINOID; RISK;

EID: 47649113067     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.03.011     Document Type: Review

References (68)

1. World Health Organization. Obesity and Overweight Fact Sheet No. 311; 2006. http://www.who.int/mediacentre/factsheets/fs311/en/print.html [accessed September 8, 2007].
2. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005;366:1640-9
3. Lau D.C., Dhillon B., Yan H., Szmitko P.E., and Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 288 (2005) H2031-H2041
4. Szmitko P.E., Teoh H., Stewart D.J., and Verma S. Adiponectin and cardiovascular disease. Am J Physiol Heart Circ Physiol 292 (2007) H1655-H1663
5. Pagotto U., Marsicano G., Cota D., Lutz B., and Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27 (2006) 73-100
6. Gaoni Y., and Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86 (1964) 1646-1647
7. Pacher P., Batkai S., and Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58 (2006) 389-462
8. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
9. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
10. Fride E., Foox A., Rosenberg E., et al. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. Eur J Pharmacol 461 (2003) 27-34
11. Lutz B. Molecular biology of cannabinoid receptors. Prostaglandins Leukot. Essent Fatty Acids 66 (2002) 123-142
12. Howlett A.C., Johnson M.R., Melvin L.S., and Milne G.M. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol Pharmacol 33 (1988) 297-302
13. Derkinderen P., Ledent C., Parmentier M., and Girault J.A. Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. J Neurochem 77 (2001) 957-960
14. Daaka Y., Zhu W., Friedman H., and Klein T.W. Induction of interleukin-2 receptor alpha gene by delta9-tetrahydrocannabinoid is mediated by nuclear factor kappaB and CBI cannabinoid receptor. DNA Cell Biol 16 (1997) 301-309
15. Rueda D., Galve-Roperh I., Haro A., and Guzman M. The CB1 cannabinoid receptor is coupled to the activation of c-JUN N-terminal kinase. Mol Pharmacol 58 (2000) 814-820
16. Gomez Del Pulgar T., De Ceballos M.L., Guzman M., and Velasco G. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 277 (2002) 36527-36533
17. Herkenham M., Lynn A.B., Little M.D., et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87 (1990) 1932-1936
18. Osei-Hyiaman D., DePetrillo M., Pacher P., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115 (2005) 1298-1305
19. Pertwee R.G. Cannabinoids and the gastrointestinal tract. Gut 48 (2001) 859-867
20. 2+ signals and insulin secretion in pancreatic β-cell. Cell Calcium 39 (2005) 155-162
21. Cota D., Marsicano G., Tschoep M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112 (2003) 423-431
22. Liu J., Gao B., Mirshahi F., et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346 (2000) 835-840
23. 2+ channel current. Am J Physiol 266 (1999) H2085-H2093
24. Van Sickle M.D., Duncan M., Kingsley P.J., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005) 329-332
25. Roche R., Hoareau L., Bes-Houtmann S., et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 126 (2006) 177-187
26. Blazquez C., Casanova M.L., Planas A., et al. Inhibition of tumour angiogenesis by cannabinoids. FASEB J 17 (2003) 529-531
27. Berry E.M., and Mechoulam R. Tetrahyrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 95 (2002) 185-190
28. 9-THC. Physiol Behav 65 (1998) 343-346
29. 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav 71 (2002) 333-340
30. Greenberg I., Kuehnle J., Mendelson J.H., and Bernstein J.G. Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology 49 (1976) 79-84
31. Foltin R.W., Brady J.V., and Fischman M.W. Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav 25 (1986) 577-582
32. Williams C.M., and Kirkham T.C. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology 143 (1999) 315-317
33. Kirkham T.C., Williams C.M., Fezza F., and Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136 (2002) 550-557
34. Di Marzo V., Goparaju S.K., Wang L., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
35. Colombo G., Agabio R., Diaz G., et al. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 63 (1998) L113-L117
36. Bensaid M., Gary-Bobo M., Esclangon A., et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63 (2003) 908-914
37. Ravinet-Trillou C., Delgorge C., Menet C., Arnone M., and Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28 (2004) 640-648
38. Jbilo O., Ravinet-Trillou C., Arnone M., et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19 (2005) 1567-1569
39. Engeli S., Bohnke J., Feldpausch M., et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54 (2005) 2838-2843
40. Cote M., Matias I., Lemieux I., et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obese (Lond) 31 (2007) 692-699
41. Bluher M., Engeli S., Kloting N., et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55 (2006) 3053-3060
42. Sipe J.C., Waalen J., Gerber A., and Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes Relat Metab Disord 29 (2005) 755-759
43. Gazzero P., Caruso M.G., Notarnicola M., et al. Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population. Int J Obes (Lond) 31 (2007) 908-912
44. Pacher P., Batkai S., and Kunos G. Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology 48 (2005) 1130-1138
45. Varga K., Lake K., Martin B.R., and Kunos G. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 278 (1995) 279-283
46. Ledent C., Valverde O., Cossu G., et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 383 (1999) 401-404
47. Niederhoffer N., Schmid K., and Szabo B. The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn Schmiedebergs Arch Pharmacol 367 (2003) 434-443
48. Deutsch D.G., Goligorsky M.S., Schmid P.C., et al. physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 100 (1997) 1538-1546
49. Varga K., Wagner J.A., Bridgen D.T., and Kunos G. Platelet- and macrophage-derived endogenouscannabinoids are involved in endotoxin-induced hypotension. FASEB J 12 (1998) 1035-1044
50. Wagner J.A., Varga K., Ellis E.F., et al. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390 (1997) 518-521
51. Wagner J.A., Hu K., Bauersachs J., et al. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol 38 (2001) 2048-2054
52. Batkai S., Pacher P., Osei-Hyiaman D., et al. Endocannabinoids acting at CB1 receptors regulate cardiovascular function in hypertension. Circulation 110 (2004) 1996-2002
53. Szmitko P.E., Wang C.H., Weisel R.D., et al. New markers of inflammation and endothelial cell activation. Circulation 108 (2003) 1917-1923
54. Steffens S., Veillard N.R., Arnaud C., et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434 (2005) 782-786
55. Szmitko P.E., and Verma S. Does cannabis hold the key to treating cardiometabolic disease?. Nat Clin Pract Cardiovasc Med 3 (2006) 116-117
56. Perwitz N., Fasshauer M., and Klein J. Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm Metab Res 38 (2006) 356-358
57. Bensaid M., Gary-Bobo M., Esclangon A., et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats in cultured adipocyte cells. Mol Pharmacol 63 (2003) 908-914
58. Osei-Hyiaman D., Depetrillo M., Harvey-White J., et al. Cocaine- and amphetamine-related transcript peptide is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology 81 (2005) 273-282
59. Padwal R.S., and Majumdar S.R. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369 (2007) 71-77
60. The RIO-North American Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
61. The RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
62. The Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
63. Scheen A.J., et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes. Lancet 368 (2006) 1160-1172
64. Van Gaal L., Pi-Sunyer X., Despres J.P., McCarthy C., and Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31 Suppl. 2 (2008) S229-S2240
65. FDA Briefing Document. NDA 21-888. Zimulti (rimonabant) Tablets, 20 mg. Sanofi Aventis. Advisory Committee; June 2007, Available at: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-fda-backgrounder.pdf[accessed September 8, 2007].
66. STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant-the Intravascular Ultrasound Study), Available at:http://www.clinicaltrials.gov/ct/show/NCT00124332?order=5 [accessed September 8, 2007].
67. CRESCENDO (Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints) and Outcomes, Available at: http://www.clinicaltrials.gov/ct/show/NCT00263042?order=2 [accessed September 8, 2007].
68. STRADIVARIUS Investigators. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299 (2008) 1547-1560